Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.35 |
| ▸ | SCN4A | P35499 | 1/20 | 0.34 |
| ▸ | DPP4 | P27487 | 3/20 | 0.32 |
| ▸ | DPP7 | Q9UHL4 | 2/20 | 0.32 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.32 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.32 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.32 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.32 |
| ▸ | PRCP | P42785 | 1/20 | 0.31 |
| ▸ | NOS2 | P35228 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16620345 | 0.88 | SCN4A (0.38) | SCN4ADPP7PRCPNOS2 | |
| SCHEMBL27740316 | 0.85 | SCN4A (0.33) | SCN4ANOS2 | |
| SCHEMBL2952396 | 0.81 | DPP4 (0.35) | SCN4ADPP4DPP7DPP8DPP9 | |
| SCHEMBL10793329 | 0.81 | GSR (0.38) | SCN4ADPP4DPP7DPP8DPP9 | |
| SCHEMBL3359438 | 0.79 | SCN4A (0.42) | SCN4ADPP4DPP7DPP8DPP9 | |
| SCHEMBL10791037 | 0.79 | CTSC (0.47) | SLC7A5SCN4ADPP4DPP7DPP8 | |
| SCHEMBL8720607 | 0.77 | SLC7A5 (0.33) | SLC7A5SCN4ASLC1A3SLC1A2 | |
| SCHEMBL11287698 | 0.76 | SCN4A (0.36) | SCN4A | |
| SCHEMBL21067674 | 0.75 | F2 (0.39) | SCN4A | |
| SCHEMBL21067306 | 0.74 | GHSR (0.49) | SCN4A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0142231-B1 | PROCESS FOR PRODUCING SEQUENTIAL POLYAMINO ACID RESIN | NITTO BOSEKI CO., LTD. (JP) | 1987-11-11 | — | — | EP | claimed |
| EP-0142231-A1 | Process for producing sequential polyamino acid resin | NITTO BOSEKI CO., LTD. (JP) | 1985-05-22 | — | — | EP | claimed |
| US-20160263235-A1 | PEPTIDE THERAPEUTIC CONJUGATES AND USES THEREOF | ANGIOCHEM INC (CA) | 2016-09-15 | — | — | US | disclosed |
| EP-2794663-A1 | PEPTIDE THERAPEUTIC CONJUGATES AND USES THEREOF | Angiochem Inc. (CA) | 2014-10-29 | — | — | EP | disclosed |
| CN-103665170-A | Peptide therapeutic conjugates and uses thereof | ANGIOCHEM INC | 2014-03-26 | — | — | CN | disclosed |
| CN-102348723-A | Peptide therapeutic agent conjugates and uses thereof | ANGIOCHEM INC | 2012-02-08 | — | — | CN | disclosed |
| US-20110288011-A1 | PEPTIDE THERAPEUTIC CONJUGATES AND USES THEREOF | ANGIOCHEM INC. (CA) | 2011-11-24 | — | — | US | disclosed |
| WO-2010063124-A1 | PEPTIDE THERAPEUTIC CONJUGATES AND USES THEREOF | ANGIOCHEM INC. (CA) | 2010-06-10 | — | — | WO | disclosed |
| US-4596819-A | Antidepressive agents | WARNER-LAMBERT COMPANY (US) | 1986-06-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160263235-A1 | PEPTIDE THERAPEUTIC CONJUGATES AND USES THEREOF | VIP, SLC1A5, SLC47A1 | SLC7A5 102/4885SCN4A 2143/4885DPP4 302/4885 |
| US-20110288011-A1 | PEPTIDE THERAPEUTIC CONJUGATES AND USES THEREOF | VIP, SLC1A5, SLC47A1 | SLC7A5 102/4885SCN4A 2143/4885DPP4 302/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.